Condition: Hepatic Cancer · Surgery · Sponsor: Second Affiliated Hospital of Guangzhou Medical University
This trial is designed to investigate the safety, response rates and survival outcomes of patients with hepatocellular carcinoma by delivery of CTLA4 and PD1 or PDL1 antibodies combination through CT-guided intra-tumor (IT) injection.
This description comes directly from the study's public registry record.
Zhenfeng Zhang, MD, PhD · +862039195966 · zhangzhf@gzhmu.edu.cn
Bingjia He, MD · +862039195965 · 464677938@qq.com
Always discuss trial participation with your own doctor first.
| The Second Affiliated Hospital of Guangzhou Medical University | Guanzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06492408